DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Busbee BG, Ho AC, Brown DM. et al.
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology 2013;
120: 1046-1056
doi:10.1016/j.ophtha.2012.10.014
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.